MGAT5 and breast cancer: Consistently, in the early-stages of these PyMT Mgat5−/− mammary tumours they also show lower levels of activation of the PI3K/AKT1signaling [87], and the cell lines derived from the PyMT Mgat5−/− are less responsive to insulin-like growth factor (IGF) [89].